4. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy 译：动态监测循环肿瘤DNA 揭示接受 CAR T 细胞治疗的复发或难治性大 B 细胞淋巴瘤患者的结果和基因组变化 作者列表:Zou H;L...
Cellular therapy increases survival in recurring B-cell lymphoma: Clinical trialhttps://medicalxpress.com/news/2024-02-cellular-therapy-survival-recurring-cell.html版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不...
Gilead’s Kite invests $285M more, expands Arcellx CAR T deal to include lymphoma Nov. 15, 2023 No Comments If there had been any lingering market concerns following the temporary partial clinical hold earlier this year for Arcellx Inc.’s multiple myeloma CAR T-cell therapy, CART-ddBCMA...
研究成果以“Phase 1 Trial of Prizloncabtagene Autoleucel, a CD19/20 CAR-T for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma”发表在《Blood》(IF:21.0,JCR一区/中科院一区)。 同济大学附属同济医院李萍教授、梁爱斌教授分别为该高水平临床...
Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or ...
Yescarta® (CD19 CAR-T)ApprovedDiffuse Large B-Cell Lymphoma, Primary mediastinal large B cell lymphoma and transformed follicular lymphoma Yescarta® (CD19 CAR-T)Phase IINon-Hodgkin lymphoma, mantle cell lymphoma Yescarta® (CD19 CAR-T)Phase IIIAcute lymphoblastic leukemia, B-cell lymphoma ...
and Drug Administration has approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL...
We previously developed an in vitro system to monitor T-cell dysfunction induced by continuous bispecific antibody (BsAb) exposure in a clinically relevant B-cell lymphoma model [22]. It is unknown if AdCAR T cells react to CONT stimulation in the same way as conventional CAR T cells. Here...
2025年3月2日,科济生物研发的一款CAR-T疗法——satricabtagene autoleucel(简称“satri-cel”,编号CT041),获中国国家药品监督管理局(NMPA)药品审评中心(CDE)授予突破性疗法认定(BTD),用于既往接受至少两种疗法失败的Claudin18.2阳性的晚期胃/胃食管连接部癌(G/GEJ)的治疗。
2023年7月,Nature medicine期刊上发表了题为“CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results”的研究论文,旨在探究阿那白滞素预防性疗法对于已经接受抗CD19 CAR-T细...